From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Proteinkinase G inhibitor-1 (Compound 270) is a mycobacterial proteinkinase Ginhibitor, with an IC50 of 0.9 μM. Proteinkinase G inhibitor-1 can be used for mycobacterial infection research .
HA-100 is a potent proteinkinaseinhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent proteinkinase (PKG), cAMP-dependent proteinkinase (PKA), proteinkinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCKinhibitor .
Proteinkinase D inhibitor 1 (compound 17m) is a pan-PKDinhibitor, with IC50 values ranging from 17 to 35 nM. Proteinkinase D inhibitor 1inhibits PKD-dependent cortactin phosphorylation .
HA-100 hydrochloride is a potent proteinkinaseinhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent proteinkinase (PKG), cAMP-dependent proteinkinase (PKA), proteinkinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCKinhibitor .
HA-100 dihydrochloride is a potent proteinkinaseinhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent proteinkinase (PKG), cAMP-dependent proteinkinase (PKA), proteinkinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCKinhibitor .
RIP2 kinaseinhibitor 1 (compound 11) is a potent and selective receptor interacting protein 2 (RIP2)kinaseinhibitor with an IC50 of 0.03 μM for RIP2 FP. RIP2 kinaseinhibitor 1 is used for autoinflammatory disorders .
Pim-1/2 kinaseinhibitor 1 is an orally active pim-1/2 kinaseinhibitor. Pim-1/2 kinaseinhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim proteinkinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinaseinhibitor 1 can be used in study of cancer, especially prostate cancer .
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
[Ala286]-Calmodulin-Dependent ProteinKinase II (281-302) is a modified fragment of calcium/calmodulin-dependent proteinkinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent ProteinKinase II (281-302) can be used to develop more potent CaMKIIinhibitors .
TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated proteinkinasekinasekinasekinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
EML4-ALK kinaseinhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase(EML4-ALK), with an IC50 of 1 nM .
Vibsanin A, a proteinkinase C (PKC) activator, exhibits anti-proliferative activity against human cancer cell lines. Vibsanin A is also a HSP90inhibitor .
FIM-1 is a fluorescent PKC (proteinkinase C) probe that can be used for mitochondrial staining. FIM-1 inhibits PKC and acts as ATP-competitive catalytic site inhibitor .
Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .
Ilaprazole (IY-81149) sodium is an orally active proton pumpinhibitor. Ilaprazole sodium irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Ilaprazole (IY-81149) sodium hydrate is an orally active proton pumpinhibitor. Ilaprazole sodium hydrate irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Ilaprazole (IY-81149) is an orally active proton pumpinhibitor. Ilaprazole irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Ilaprazole (Standard) is the analytical standard of Ilaprazole. This product is intended for research and analytical applications. Ilaprazole (IY-81149) is an orally active proton pumpinhibitor. Ilaprazole irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Beclin1-ATG14L interaction inhibitor 1 (com 19) is a selective Beclin1-ATG14L interaction inhibitor. This protein interaction mechanism specifically targets complex I of the lipid kinase VPS34 without affecting complex II. Because the integrity of VPS34 complex II depends on the Beclin 1-UVRAG interaction. Beclin1-ATG14L interaction inhibitor 1 can disrupt the formation of VPS34 complex I and inhibit autophagy, but does not affect complex II-related vesicle transport .
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Srcinhibitor .
FIM-1 is a fluorescent PKC (proteinkinase C) probe that can be used for mitochondrial staining. FIM-1 inhibits PKC and acts as ATP-competitive catalytic site inhibitor .
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Srcinhibitor .
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
[Ala286]-Calmodulin-Dependent ProteinKinase II (281-302) is a modified fragment of calcium/calmodulin-dependent proteinkinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent ProteinKinase II (281-302) can be used to develop more potent CaMKIIinhibitors .
Vibsanin A, a proteinkinase C (PKC) activator, exhibits anti-proliferative activity against human cancer cell lines. Vibsanin A is also a HSP90inhibitor .
The CDKN1B protein is a key cell cycle regulator that inhibits CDK2 when bound to cyclin A, thereby inhibiting G1 phase progression. It exhibits significant inhibitory effects on cyclin E- and cyclin A-CDK2 complexes. CDKN1B Protein, Human (His) is the recombinant human-derived CDKN1B protein, expressed by E. coli , with N-6*His labeled tag. The total length of CDKN1B Protein, Human (His) is 198 a.a., with molecular weight of ~30.0 kDa.
PKCi protein has adenosine 5'-monophosphate amidase activity and can hydrolyze compounds such as AMP-NH2. It also acts on AMP-morpholidate, GMP-morpholidate, lysyl-AMP, Met-AMP, His-AMP, Asp-AMP, lysyl-GMP and AMP-N-alanine methyl ester. PKCi Protein, Human is the recombinant human-derived PKCi protein, expressed by E. coli , with tag free. The total length of PKCi Protein, Human is 126 a.a., .
PKCi protein has adenosine 5'-monophosphate amidase activity and can hydrolyze compounds such as AMP-NH2. It also acts on AMP-morpholidate, GMP-morpholidate, lysyl-AMP, Met-AMP, His-AMP, Asp-AMP, lysyl-GMP and AMP-N-alanine methyl ester. PKCi Protein, Human (His) is the recombinant human-derived PKCi protein, expressed by E. coli , with N-6*His labeled tag. The total length of PKCi Protein, Human (His) is 126 a.a., .
HINT1; HINT; PKCI1; PRKCNH1; Histidine triad nucleotide-binding Protein 1; Adenosine 5'-monophosphoramidase; Proteinkinase C inhibitor 1; Proteinkinase C-interacting Protein 1; PKCI-1
WB, ICC/IF, IP
Human
HINT1 Antibody (YA2983) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2983), targeting HINT1, with a predicted molecular weight of 14 kDa (observed band size: 14 kDa). HINT1 Antibody (YA2983) can be used for WB, ICC/IF, IP experiment in human background.
CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinaseinhibitor 1; CDK-interacting Protein 1; Melanoma differentiation-associated Protein 6; MDA-6; p21
WB, ICC/IF
Human, Mouse, Rat
p21 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 18 kDa, targeting to p21. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.
CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinaseinhibitor 1; CDK-interacting Protein 1; Melanoma differentiation-associated Protein 6; MDA-6; p21
WB
Human, Mouse
p21 Antibody (YA254) is a non-conjugated and Rabbit origined monoclonal antibody about 18 kDa, targeting to p21. It can be used for WB assays with tag free, in the background of Human, Mouse.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
![[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)](http://file.medchemexpress.eu/product_pic/hy-p10499.gif)
